ApoCell, Inc.'s Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
6/8/2007 12:51:01 PM
ApoCell, Inc. presented the results of a study conducted by researchers at the University of Chicago and ApoCell at the 2007 annual meeting of the American Society of Clinical Oncology (ASCO) held in Chicago in early June. The study showed that ApoCell's advanced pharmacodynamic biomarker assay technology provides reliable predictive data of clinical response. This study showed the benefit of treating aggressive head and neck cancer patients with a combination of targeted molecular drugs.
comments powered by